Discover Ono Pharmaceutical's groundbreaking patent for autophagy-inhibiting compounds, targeting various cancers with innovative MEK inhibitors like selumetinib.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

Researchers at the University of Massachusetts Amherst and UMass Chan Medical School have demonstrated in mice a new method ...

They highlighted a type of cancer drug called MEK inhibitors, which work by blocking specific proteins from growing, as a potential candidate. And tests, conducted by the researchers, found MEK ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

近年来随着治疗靶点的发现和新型靶向药物的不断研发，肿瘤治疗已步入精准治疗新时代。近日，2024 年世界肺癌大会（WCLC）和欧洲肿瘤内科学会（ESMO）年会陆续召开，带来肿瘤领域最新前沿进展。会议中，针对 BRAF、MET 14 ...

Discover Ikena Oncology's groundbreaking patent for anti-TREM1 antibodies, designed to boost immune responses and revolutionize cancer treatment.

CaMKII activates the HRI/eIF2α signaling pathway and inhibits the proteotoxicity induced by proteasome inhibition through ...